WNT signaling in glioblastoma and therapeutic opportunities

Laboratory Investigation

Volumn 96, Issue 2, 2016, Pages 137-150

  Lee, Yeri ^a   Lee, Jin Ku ^b   Ahn, Sun Hee ^a   Lee, Jeongwu ^c   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; ANTIBODY; APC PROTEIN; AXIN; BETA CATENIN; CYCLIN D1; DICKKOPF 1 PROTEIN; DISHEVELLED 2; FRIZZLED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN INHIBITOR; RAC PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR RECEPTOR; SMALL MOLECULE INHIBITOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; WNT PROTEIN; WNT11 PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN;

ARTICLE; CALCIUM CELL LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL FATE; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL POLARITY; CELL SURFACE; CLINICAL TRIAL (TOPIC); DROSOPHILA; EPIGENETICS; GLIOBLASTOMA; HAIR FOLLICLE; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; STEM CELL NICHE; TUMOR INVASION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84955598003     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.140     Document Type: Article

References (167)

1. Kalani MY, Cheshier SH, Cord BJ et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Natl Acad Sci USA 2008;105: 16970-16975.
2. Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18: 523-527.
3. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-129.
4. Pulvirenti T, Van Der Heijden M, Droms LA et al. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res 2011;71:7280-7290.
5. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 2002;297:365-369.
6. Zechner D, Fujita Y, Hulsken J et al. Beta-catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 2003;258:406-418.
7. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61: 215-225.
8. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
9. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
10. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
11. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 2000;97:6242-6244.
12. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-626.
13. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in Pdgfra, Idh1, Egfr, and Nf1. Cancer Cell 2010;17: 98-110.
14. Kahlert UD, Maciaczyk D, Doostkam S et al. Activation of canonical Wnt/Beta-catenin signaling enhances in vitro motility of glioblastoma cells by activation of Zeb1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012;325:42-53.
15. Zhang JX, Zhang J, Yan W et al. Unique genome-wide map of Tcf4 and Stat3 targets using Chip-Seq reveals their association with new molecular subtypes of glioblastoma. Neuro Oncol 2013;15: 279-289.
16. Seymour T, Nowak A, Kakulas F. Targeting aggressive cancer stem cells in glioblastoma. Front Oncol 2015;5:159.
17. Suva ML, Rheinbay E, Gillespie SM et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014;157:580-594.
18. Wang J, Ma Y, Cooper MK. Cancer stem cells in glioma: challenges and opportunities. Transl Cancer Res 2013;2:429-441.
19. Auffinger B, Spencer D, Pytel P et al. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 2015;15:741-752.
20. Brennan C, Momota H, Hambardzumyan D et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4:e7752.
21. Yu CY, Liang GB, Du P et al. Lgr4 promotes glioma cell proliferation through activation of Wnt signaling. Asian Pac J Cancer Prev 2013;14: 4907-4911.
22. Gong A, Huang S. Foxm1 and Wnt/Beta-catenin signaling in glioma stem cells. Cancer Res 2012;72:5658-5662.
23. Zhang K, Zhang J, Han L et al. Wnt/Beta-catenin signaling in glioma. J Neuroimmune Pharmacol 2012;7:740-749.
24. Trevino M, Stefanik DJ, Rodriguez R et al. Induction of canonical wnt signaling by alsterpaullone is sufficient for oral tissue fate during regeneration and embryogenesis in Nematostella Vectensis. Dev Dyn 2011;240:2673-2679.
25. Sumiyoshi E, Takahashi S, Obata H et al. The beta-catenin Hmp-2 functions downstream of Src in parallel with the Wnt pathway in early embryogenesis of C. Elegans. Dev Biol 2011;355:302-312.
26. Nakamura T, Akiyama T. Role of the Wnt signaling network in embryogenesis and tumorigenesis. Seikagaku 2005;77:5-19.
27. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398.
28. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004;9:119-131.
29. Smalley MJ, Dale TC. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999;18:215-230.
30. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99-109.
31. Sareddy GR, Panigrahi M, Challa S et al. Activation of Wnt/Beta-Catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int 2009;55:307-317.
32. Liu C, Tu Y, Sun X et al. Wnt/Beta-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 2011;11:105-112.
33. Zhang N, Wei P, Gong A et al. Foxm1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011;20:427-442.
34. Semenov MV, Habas R, Macdonald BT et al. Snapshot: noncanonical Wnt signaling pathways. Cell 2007;131:1378.
35. Cohen ED, Tian Y, Morrisey EE. Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. Development 2008;135:789-798.
36. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010;106:1798-1806.
37. Simons M, Mlodzik M. Planar cell polarity signaling: from fly development to human disease. Annu Rev Genet 2008;42:517-540.
38. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009;19:119-129.
39. Medyouf H, Ghysdael J. The Calcineurin/Nfat signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008;7:297-303.
40. Hogan PG, Chen L, Nardone J et al. Transcriptional regulation by calcium, calcineurin, and Nfat. Genes Dev 2003;17:2205-2232.
41. Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
42. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003;94:225-229.
43. Fattet S, Haberler C, Legoix P et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94.
44. Austinat M, Dunsch R, Wittekind C et al. Correlation between beta-catenin mutations and expression of wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008;7:21.
45. Kim YD, Park CH, Kim HS et al. Genetic alterations of wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastro-enterol Hepatol 2008;23:110-118.
46. Sparks AB, Morin PJ, Vogelstein B et al. Mutational analysis of the Apc/Beta-Catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58: 1130-1134.
47. Aust DE, Terdiman JP, Willenbucher RF et al. The Apc/Beta-Catenin pathway in ulcerative colitis-related colorectal carcinomas: a muta-tional analysis. Cancer 2002;94:1421-1427.
48. Sieber OM, Heinimann K, Gorman P et al. Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at Apc. Proc Natl Acad Sci USA 2002;99:16910-16915.
49. Zurawel RH, Chiappa SA, Allen C et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-899.
50. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59: 333-337.
51. Yokota N, Nishizawa S, Ohta S et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 2002;101:198-201.
52. Baeza N, Masuoka J, Kleihues P et al. Axin1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003;22:632-636.
53. Silva R, Marie SK, Uno M et al. Ctnnb1, Axin1 and Apc expression analysis of different medulloblastoma variants. Clinics (Sao Paulo) 2013;68:167-172.
54. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
55. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
56. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
57. Shou J, Ali-Osman F, Multani AS et al. Human Dkk-1, a gene encoding a wnt antagonist, responds to dna damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 2002;21:878-889.
58. Roth W, Wild-Bode C, Platten M et al. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000;19:4210-4220.
59. Schiefer L, Visweswaran M, Perumal V et al. Epigenetic regulation of the secreted frizzled-related protein family in human glioblastoma multiforme. Cancer Gene Ther 2014;21:297-303.
60. Foltz G, Yoon JG, Lee H et al. Epigenetic regulation of wnt pathway antagonists in human glioblastoma Multiforme. Genes Cancer 2010;1: 81-90.
61. Korinek V, Barker N, Moerer P et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19:379-383.
62. Andl T, Reddy ST, Gaddapara T et al. Wnt signals are required for the initiation of hair follicle development. Dev Cell 2002;2: 643-653.
63. Gat U, DasGupta R, Degenstein L et al. De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998;95:605-614.
64. Facchino S, Abdouh M, Bernier G. Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) 2011;3:1777-1797.
65. Gursel DB, Shin BJ, Burkhardt JK et al. Glioblastoma stem-like cells-biology and therapeutic implications. Cancers (Basel) 2011;3: 2655-2666.
66. Kanwar SS, Yu Y, Nautiyal J et al. The Wnt/Beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010;9:212.
67. Ramachandran I, Ganapathy V, Gillies E et al. Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis 2014;5:e1246.
68. Jin X, Jeon HY, Joo KM et al. Frizzled 4 Regulates Stemness and Invasiveness of Migrating Glioma Cells Established by Serial Intracranial Transplantation. Cancer Res 2011;71:3066-3075.
69. Vermeulen L, De Sousa EMF, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the micro-environment. Nat Cell Biol 2010;12:468-476.
70. Fodde R, Brabletz T. Wnt/Beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-158.
71. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014;346:1248012.
72. Holland JD, Klaus A, Garratt AN et al. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013;25:254-264.
73. Ortensi B, Setti M, Osti D et al. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther 2013;4:18.
74. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008;4:427-435.
75. Zheng H, Ying H, Wiedemeyer R et al. Plagl2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010;17:497-509.
76. Sekiya R, Maeda M, Yuan H et al. Plagl2 regulates actin cyto-skeletal architecture and cell migration. Carcinogenesis 2014;35: 1993-2001.
77. Joshi K, Banasavadi-Siddegowda Y, Mo X et al. Melk-dependent foxm1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013;31:1051-1063.
78. Lee Y, Kim KH, Kim DG et al. Foxm1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2. PLoS One 2015;10:e0137703.
79. Rheinbay E, Suva ML, Gillespie SM et al. An aberrant transcription factor network essential for wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013;3:1567-1579.
80. Goodman RM, Thombre S, Firtina Z et al. Sprinter: a novel transmembrane protein required for Wg secretion and signaling. Development 2006;133:4901-4911.
81. Augustin I, Goidts V, Bongers A et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2012;4: 38-51.
82. Bartscherer K, Pelte N, Ingelfinger D et al. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell 2006;125: 523-533.
83. Gao X, Mi Y, Ma Y et al. Lef1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal. Tumour Biol 2014;35:11505-11511.
84. Xue Y, Li L, Zhang D et al. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with Htert-dysfunction. PLoS One 2011;6:e27748.
85. Sarrio D, Franklin CK, Mackay A et al. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012;30:292-303.
86. Joost S, Almada LL, Rohnalter V et al. Gli1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res 2012;72:88-99.
87. Smit MA, Peeper DS. Zeb1 is required for trkb-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011;30:3735-3744.
88. Han SP, Kim JH, Han ME et al. Snai1 is involved in the proliferation and migration of glioblastoma cells. Cell Mol Neurobiol 2011;31: 489-496.
89. Wellner U, Schubert J, Burk UC et al. The Emt-activator Zeb1 promotes tumorigenicity by repressing stemness-inhibiting micro-RNAs. Nat Cell Biol 2009;11:1487-1495.
90. Mikheeva SA, Mikheev AM, Petit A et al. Twist1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 2010;9:194.
91. Yang HW, Menon LG, Black PM et al. Snai2/Slug promotes growth and invasion in human gliomas. BMC Cancer 2010;10:301.
92. Howe LR, Watanabe O, Leonard J et al. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 2003;63:1906-1913.
93. Kemler R, Hierholzer A, Kanzler B et al. Stabilization of beta-catenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. Development 2004;131:5817-5824.
94. Scheel C, Eaton EN, Li SH et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011;145:926-940.
95. Yue X, Lan F, Yang W et al. Interruption of beta-catenin suppresses the Egfr pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res 2010;1366:27-37.
96. Kamino M, Kishida M, Kibe T et al. Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and Mmp-2. Cancer Sci 2011;102:540-548.
97. Pu P, Zhang Z, Kang C et al. Downregulation of Wnt2 and Beta-catenin by Sirna suppresses malignant glioma cell growth. Cancer Gene Ther 2009;16:351-361.
98. Varma RR, Hector SM, Clark K et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 2005;14:925-932.
99. Anastas JN, Kulikauskas RM, Tamir T et al. Wnt5a enhances resistance of melanoma cells to targeted Braf inhibitors. J Clin Invest 2014;124: 2877-2890.
100. Peng C, Zhang X, Yu H et al. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer 2011;21:280-288.
101. Bordonaro M, Tewari S, Cicco CE et al. A switch from canonical to noncanonical wnt signaling mediates drug resistance in colon cancer cells. PLoS One 2011;6:e27308.
102. Griesmann H, Ripka S, Pralle M et al. Wnt5a-Nfat signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 2013;15: 11-22.
103. Auger N, Thillet J, Wanherdrick K et al. Genetic alterations associated with acquired temozolomide resistance in Snb-19, a human glioma cell line. Mol Cancer Ther 2006;5:2182-2192.
104. Chen MS, Woodward WA, Behbod F et al. Wnt/Beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007;120:468-477.
105. Woodward WA, Chen MS, Behbod F et al. Wnt/Beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007;104:618-623.
106. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 2010;107:3522-3527.
107. Kendziorra E, Ahlborn K, Spitzner M et al. Silencing of the Wnt transcription factor Tcf4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011;32:1824-1831.
108. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
109. Zhang N, Wu X, Yang L et al. Foxm1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 2012;18: 5961-5971.
110. Kim Y, Kim KH, Lee J et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012;92:466-473.
111. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a Cpg island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-522.
112. Watanabe K, Tachibana O, Sata K et al. Overexpression of the Egf receptor and P53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6: 217-223.
113. Ekstrand AJ, Sugawa N, James CD et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89:4309-4313.
114. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899.
115. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009;2:re6.
116. Karpel-Massler G, Schmidt U, Unterberg A et al. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res 2009;7:1000-1012.
117. Chen L, Huang K, Han L et al. Beta-Catenin/Tcf-4 complex transcrip-tionally regulates Akt1 in glioma. Int J Oncol 2011;39:883-890.
118. Ji H, Wang J, Nika H et al. Egf-induced Erk activation promotes Ck2-mediated disassociation of alpha-catenin from beta-catenin and transactivation of beta-catenin. Mol Cell 2009;36:547-559.
119. Lu Z, Ghosh S, Wang Z et al. Downregulation of caveolin-1 function by Egf leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:499-515.
120. Kong DS, Song SY, Kim DH et al. Prognostic significance of C-Met expression in glioblastomas. Cancer 2009;115:140-148.
121. Joo KM, Jin J, Kim E et al. Met signaling regulates glioblastoma stem cells. Cancer Res 2012;72:3828-3838.
122. Nabeshima K, Shimao Y, Sato S et al. Expression of C-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 1997;31:436-443.
123. Kim KH, Seol HJ, Kim EH et al. Wnt/Beta-catenin signaling is a key downstream mediator of met signaling in glioblastoma stem cells. Neuro Oncol 2013;15:161-171.
124. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3:903-911.
125. Dahmane N, Sanchez P, Gitton Y et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001;128:5201-5212.
126. Takezaki T, Hide T, Takanaga H et al. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci 2011;102:1306-1312.
127. Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29: 1408-1414.
128. Taylor MD, Northcott PA, Korshunov A et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123: 465-472.
129. Zinke J, Schneider FT, Harter PN et al. Beta-Catenin-Gli1 Interaction regulates proliferation and tumor growth in medulloblastoma. Mol Cancer 2015;14:17.
130. Taylor MD, Liu L, Raffel C et al. Mutations in Sufu predispose to medulloblastoma. Nat Genet 2002;31:306-310.
131. Reifenberger G, Reifenberger J, Ichimura K et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of Cdk4, Sas, and Mdm2. Cancer Res 1994;54:4299-4303.
132. Collins VP. Gene amplification in human gliomas. Glia 1995;15: 289-296.
133. Reifenberger G, Ichimura K, Reifenberger J et al. Refined mapping of 12q13-Q15 amplicons in human malignant gliomas suggests cdk4/sas and mdm2 as independent amplification targets. Cancer Res 1996;56:5141-5145.
134. Werner CA, Dohner H, Joos S et al. High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. Am J Pathol 1997;151:335-342.
135. Rao PH, Houldsworth J, Dyomina K et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998;92: 234-240.
136. Chandra V, Das T, Gulati P et al. Hedgehog signaling pathway is active in Gbm with Gli1 Mrna expression showing a single continuous distribution rather than discrete high/low clusters. PLoS One 2015;10: e0116390.
137. Rossi M, Magnoni L, Miracco C et al. Beta-cCatenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 2011;11: 753-761.
138. He J, Sheng T, Stelter AA et al. Suppressing Wnt signaling by the Hedgehog pathway through Sfrp-1. J Biol Chem 2006;281: 35598-35602.
139. Sottoriva A, Spiteri I, Piccirillo SG et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013;110:4009-4014.
140. He B, Reguart N, You L et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005;24:3054-3058.
141. You L, He B, Xu Z et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004;64:5385-5389.
142. Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against Fzd 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005;24:6201-6212.
143. Fujii N, You L, Xu Z et al. An antagonist of Dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007;67:573-579.
144. Yoshizumi T, Ohta T, Ninomiya I et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of Ht-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004;25:631-639.
145. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/creb-binding protein transcription. Proc Natl Acad Sci USA 2004;101:12682-12687.
146. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-107.
147. Liu J, Stevens J, Matsunami N et al. Targeted degradation of beta-catenin by chimeric F-Box fusion proteins. Biochem Biophys Res Commun 2004;313:1023-1029.
148. Lazarova DL, Chiaro C, Wong T et al. Cbp activity mediates effects of the histone deacetylase inhibitor butyrate on Wnt activity and apoptosis in colon cancer cells. J Cancer 2013;4: 481-490.
149. Su Y, Ishikawa S, Kojima M et al. Eradication of pathogenic beta-catenin by Skp1/Cullin/F Box ubiquitination machinery. Proc Natl Acad Sci USA 2003;100:12729-12734.
150. Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 2006;23:873-881.
151. Courad JP, Besse D, Delchambre C et al. Acetaminophen distribution in the rat central nervous system. Life Sci 2001;69:1455-1464.
152. Zhang X, Morham SG, Langenbach R et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-459.
153. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate Beta-Catenin/Tcf-4 signaling. Oncogene 2001;20:645-653.
154. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
155. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
156. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899.
157. Lan F, Yue X, Han L et al. Antitumor effect of aspirin in glioblastoma cells by modulation of beta-catenin/T-cell factor-mediated transcrip-tional activity. J Neurosurg 2011;115:780-788.
158. Sareddy GR, Kesanakurti D, Kirti PB et al. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/Beta-Catenin/Tcf signaling pathway in human glioblastoma cells. Neuro-chem Res 2013;38:2313-2322.
159. De Robertis A, Valensin S, Rossi M et al. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol Cancer Ther 2013;12:1180-1189.
160. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes wnt signalling. Nature 2009;461:614-620.
161. He B, You L, Uematsu K et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004;6:7-14.
162. Hanaki H, Yamamoto H, Sakane H et al. An Anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther 2012;11:298-307.
163. Fontenot E, Rossi E, Mumper R et al. A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Mol Cancer Ther 2013;12:685-695.
164. Safholm A, Tuomela J, Rosenkvist J et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 2008;14:6556-6563.
165. Fukukawa C, Hanaoka H, Nagayama S et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against Fzd10. Cancer Sci 2008;99:432-440.
166. Hernandez-Pedro NY, Rangel-Lopez E, Vargas Felix G et al. An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis 2013;2013:716813.
167. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37: 48-57.